Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer

Annals of Oncology

Volumn 27, Issue 2, 2016, Pages 225-232

  Donnem, Tom ^a,b   Kilvaer, T K ^a   Andersen, S ^a   Richardsen, E ^a,b   Paulsen, E E ^a,b   Hald, S M ^b   Al Saad, S ^a,b   Brustugun, O T ^c   Helland, A ^c   Lund Iversen, M ^c   Solberg, S ^c   Gronberg, B H ^d,e   Wahl, S G F ^d   Helgeland, L ^f   Flotten O ^f   Pohl, M ^g   Al Shibli, K ^h   Sandanger, T M ^b   Pezzella, F ⁱ   Busund, L T ^a,b   Bremnes, R M ^a,b   more..

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g Rigshospitalet   (Denmark)

^h NORDLAND HOSPITAL   (Norway)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Immunoscore; Lung cancer; NSCLC; T cells; TNM I

Indexed keywords

BIOLOGICAL MARKER; CD3 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CLINICAL DECISION MAKING; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE DIFFERENTIATION; NON SMALL CELL LUNG CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOLOGY; LUNG NEOPLASMS; MORTALITY; NEOPLASM METASTASIS; PATHOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TUMOR MICROENVIRONMENT;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TUMOR MICROENVIRONMENT;

EID: 84961672262     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv560     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Brustugun OT, Moller B, Helland A. Years of life lost as a measure of cancer burden on a national level. Br J Cancer 2014; 111: 1014-1020.
3. Goldstraw P, Ball D, Jett JR et al. Non-small-cell lung cancer. Lancet 2011; 378: 1727-1740.
4. Goldstraw P, Crowley J, Chansky K et al. The IASLC Lung Cancer Staging Project:proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714.
5. Donnem TP, Hald SM, Paulsen EE et al. Stromal CD8+ T cell density-a promising supplement to TNM staging in non-small cell lung cancer. Clin Cancer Res 2015; 21: 2635-2643.
6. Bremnes RM, Al-Shibli K, Donnem T et al. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 2011; 6: 824-833.
7. Fridman WH, Pages F, Sautes-Fridman C et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306.
8. Anagnostou VK, Brahmer JR. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res 2015; 21: 976-984.
9. Remark R, Becker C, Gomez JE et al. The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am J Respir Crit Care Med 2015; 191: 377-390.
10. Galon J, Pages F, Marincola FM et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012; 10: 205.
11. Galon J, Angell HK, Bedognetti D et al. The continuum of cancer immunosurveillance:prognostic, predictive, and mechanistic signatures. Immunity 2013; 39: 11-26.
12. Galon J, Mlecnik B, Bindea G et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014; 232: 199-209.
13. Salgado R, Denkert C, Demaria S et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26: 259-271.
14. Kim MY, Koh J, Kim S et al. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer 2015; 88: 24-33.
15. Schalper KA, Brown J, Carvajal-Hausdorf D et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst 2015 Feb 3 [epub ahead of print], doi: 10.1093/jnci/dju435.
16. Alifano M, Mansuet-Lupo A, Lococo F et al. Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected nonsmall cell lung cancer. PLoS One 2014; 9: e106914.
17. Goc J, Germain C, Vo-Bourgais TK et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res 2014; 74: 705-715.
18. Suzuki K, Kadota K, Sima CS et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol 2013; 31: 490-498.
19. Kayser G, Schulte-Uentrop L, Sienel W et al. Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas. Lung Cancer 2012; 76: 445-451.
20. Ilie M, Hofman V, Ortholan C et al. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer 2012; 118: 1726-1737.
21. Sterlacci W, Wolf D, Savic S et al. High transforming growth factor beta expression represents an important prognostic parameter for surgically resected non-small cell lung cancer. Hum Pathol 2012; 43: 339-349.
22. Horne ZD, Jack R, Gray ZT et al. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res 2011; 171: 1-5.
23. Kilic A, Landreneau RJ, Luketich JD et al. Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-smallcell lung cancer tumors. J Surg Res 2011; 167: 207-210.
24. Al-Shibli K, Al-Saad S, Andersen S et al. The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma. APMIS 2010; 118: 371-382.
25. Ruffini E, Asioli S, Filosso PL et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 2009; 87: 365-371.
26. Al-Shibli KI, Donnem T, Al-Saad S et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008; 14: 5220-5227.
27. Johnson SK, Kerr KM, Chapman AD et al. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 2000; 27: 27-35.
28. Duan MC, Zhong XN, Liu GN et al. The Treg/Th17 paradigm in lung cancer. J Immunol Res 2014; 2014: 730380.
29. Pages F, Kirilovsky A, Mlecnik B et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27: 5944-5951.
30. Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-2666.
31. Kallioniemi OP, Wagner U, Kononen J et al. Tissue microarray technology for highthroughput molecular profiling of cancer. Hum Mol Genet 2001; 10: 657-662.
32. Vayrynen JP, Vornanen JO, Sajanti S et al. An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer. Virchows Arch 2012; 460: 455-465.